A Novel Smad7 Genetic Variant Mapping on the Genomic Region Targeted by Mongersen Is Associated with Crohn’s Disease

Background: Down-regulation of Smad7 with a specific Smad7 antisense (AS) oligonucleotide-containing oral drug (Mongersen) was effective in pre-clinical studies and initial clinical trials in Crohn’s disease (CD) patients. A recent phase 3 trial was discontinued due to an apparent inefficacy of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Fusco, Davide, Marafini, Irene, Stolfi, Carmine, Troncone, Edoardo, Onali, Sara, Lolli, Elisabetta, Caprioli, Flavio, Mazza, Stefano, Raffaella, Cascella, Manzo, Laura, Borgiani, Paola, Giuffrida, Paolo, Di Sabatino, Antonio, Monteleone, Ivan, Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460430/
https://www.ncbi.nlm.nih.gov/pubmed/32707955
http://dx.doi.org/10.3390/biomedicines8080234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460430/
https://www.ncbi.nlm.nih.gov/pubmed/32707955
http://dx.doi.org/10.3390/biomedicines8080234

Ejemplares similares